Michael W Bennett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10825099/publications.pdf

Version: 2024-02-01

17	957	840776 11	1125743 13
papers	citations	h-index	g-index

17	17	17	987
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nerve infiltration by benign biliary glands â€“ a diagnostic dilemma. Histopathology, 2018, 72, 525-527.	2.9	0
2	Is excision biopsy of fibroadenomas based solely on size criteria warranted?. Breast Journal, 2018, 24, 981-985.	1.0	12
3	Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis. American Journal of Clinical Pathology, 2016, 145, 75-80.	0.7	10
4	An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer. British Journal of Cancer, 2016, 114, 37-43.	6.4	73
5	Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast. Breast, 2015, 24, 197-200.	2.2	28
6	Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cellsin vivo. International Journal of Cancer, 2003, 107, 209-214.	5.1	25
7	Rapid Development of a Quantitative-Competitive (qc) RT-PCR Assay Using a Composite Primer Approach. , 2002, 193, 093-102.		2
8	Immune privilege or inflammation? Insights into the Fas ligand enigma. Nature Medicine, 2001, 7, 271-274.	30.7	152
9	Interferon-? sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis. Journal of Cellular Physiology, 2000, 185, 331-338.	4.1	57
10	Altered Mechanisms of Apoptosis in Colon Cancer: Fas Resistance and Counterattack in the Tumorâ€Immune Conflict. Annals of the New York Academy of Sciences, 2000, 910, 178-195.	3.8	91
11	Interferon-Î³ sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis. , 2000, 185, 331.		1
12	The Fas counterattack: cancer as a site of immune privilege. Trends in Immunology, 1999, 20, 46-52.	7.5	218
13	Fas counter-attackâ€“the best form of tumor defense?. Nature Medicine, 1999, 5, 267-268.	30.7	74
14	Expression of Fas (CD95/APO-1) Ligand by Human Breast Cancers: Significance for Tumor Immune Privilege. Vaccine Journal, 1999, 6, 457-463.	2.6	46
15	Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. , 1998, 186, 240-246.		112
16	Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. Journal of Pathology, 1998, 186, 240-246.	4.5	3
17	The Fas Counterattack: A Molecular Mechanism of Tumor Immune Privilege. Molecular Medicine, 1997, 3, 294-300.	4.4	53